Amniotic membrane extract eye drops for eye surface diseases.

The effect of amniotic membrane extract eye drops on promoting epithelialization and suppressing inflammation in patients with ocular surface diseases.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000014055

Acronym

AME

Enrollment

Registered

2010-01-07

Start date

2006-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Now it is well accepted that amniotic membrane transplantation (AMT) as a temporary patch,or as a permanent graft is effective in treating inflammatory ocular diseases with epithelial defect. We hypothesis that amniotic membrane extract will be equally effective in treating those diseases, and also can avoid the surgical insult to the eye.

Interventions

Amniotic membrane extract (AME) eye drops are made from amniotic membrane which has been widely used as a patch or graft for ocular surface diseases. AME is applied one drop (0.1ml) every hour for the first week, then every two hours untill complete epithelialization, then 4 times a day untill inflammation subsides. The patients enrolled might have prior failed amniotic membrane transplantation (AMT).

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

ocular surface diseases with epithelial disorders and inflammation

Exclusion criteria

trichiasis, palpebral conjunctiva scar, limbal stem cell dificiency, corneal perforation

Outcome results